News

Curetis and OpGen Complete Business Combination

Amsterdam, The Netherlands, and Holzgerlingen, Germany, April 01, 2020, 10:00 pm CET – Curetis N.V. (in liquidation) (the “Company”) today announced that the business combination between the Company and OpGen Inc. (“OpGen”) has successfully been completed. The signing of the German transfer agreement implementing the transfer of 100% of the shares in Curetis GmbH to…

Read More

OpGen Announces Shareholder Approval for Business Combination with Curetis

GAITHERSBURG, Md., March 30, 2020 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, announced today that, following its Special Meeting of Shareholders held March 30, 2020, OpGen shareholders overwhelmingly voted to approve the proposed business combination with Curetis…

Read More

Curetis Begins Offering BGI’s CE-IVD Rapid Test Kit for Coronavirus in Europe

Holzgerlingen, Germany, March 16, 2020, 08:00 am CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that it starts offering a CE-IVD certified real-time PCR test kit for SARS-CoV2 (also known as 2019-nCov), the causal pathogen of Corona Virus Disease 2019 (Covid-19). The…

Read More

Curetis N.V. Reports Results of the Extraordinary General Meeting

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, March 10, 2020, 14:15 pm CET – Curetis N.V. (the “Company” and together with its subsidiaries “Curetis”), a developer of next-level molecular diagnostic solutions, today reported the results of its Extraordinary General Meeting (the “EGM”) held in Schiphol today, March 10, 2020. Shareholders adopt all…

Read More

Epigenomics Request Triggers Centers for Medicare and Medicaid Services (CMS) Plan To Cover Colorectal Cancer Blood-Based Biomarker Tests

03 Mar 2020 – MedTech Insights – The US Centers for Medicare and Medicaid Services is considering a national coverage determination for a blood-based biomarker screening test for colorectal cancer after receiving a request for a national coverage determination from Epigenomics for its Epi proColon assay. The US Centers for Medicare and Medicaid Services on…

Read More

Centers for Medicare & Medicaid Services (CMS) Open National Coverage Determination (NCD) Review Process for Epi proColon

Berlin, 28.02.2020– Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that the Centers for Medicare & Medicaid Services (CMS) have opened the National Coverage Determination (NCD) review of Epi proColon, Epigenomics’ blood test for colorectal cancer screening. This means that according to the statutes, a decision on CMS’s reimbursement of Epi proColon…

Read More

Curetis Group Company Ares Genetics and BGI Group Collaborate to Offer Next-Generation Sequencing and PCR-based Coronavirus (2019-nCoV) Testing in Europe

Vienna, Austria, Holzgerlingen, Germany, and Shenzhen, China, January 30, 2020, 08:00 am CET – Ares Genetics GmbH, a Curetis Group company, and the Chinese genomics company BGI Group today announced that the companies will collaborate in making molecular testing for the new coronavirus 2019-nCoV available in Europe. 2019-nCoV is a new coronavirus variant that has…

Read More

Curetis Launches Recently FDA-cleared Unyvero Lower Respiratory Tract (LRT) Pneumonia Pathogen Panel for Bronchoalveolar Lavage (BAL) Specimens in the U.S.

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, January 14, 2020, 08:00 am CET — Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced the U.S. launch of its Unyvero LRT BAL Lower Respiratory Tract Application Cartridge for use with bronchoalveolar lavage (BAL)…

Read More

Curetis Receives U.S. FDA 510(k) Clearance of Unyvero Lower Respiratory Tract (LRT) Test Cartridge for Bronchoalveolar Lavage (BAL) Specimens

Amsterdam, the Netherlands, Holzgerlingen, Germany, and San Diego, CA, USA, December 20, 2019, 23:30 CET — Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company has received 510(k) clearance by the U.S. Food and Drug Administration (FDA) to market its Unyvero LRT…

Read More

Ares Genetics, a Curetis Group Company, Joins NVIDIA Inception and Amazon Web Services (AWS) Activate Programs

Vienna, Austria, and Holzgerlingen, Germany, December 10, 2019, 08:00 am CET – Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that its fully-owned subsidiary Ares Genetics has joined the NVIDIA Inception program as a community member. The Inception program is designed to nurture start-ups…

Read More